Orthocell (ASX:OCC) has appointed its first four US distributors operating in Michigan, Virginia, Colorado, and Indiana, for its nerve repair device Remplir, according to a Wednesday filing with the Australian bourse.
Manufacturing and logistics are in place, with significant inventory ready to support initial sales, the filing said.
Shares of the company rose 6% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.